These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 25633662)

  • 1. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
    Lewin A; DeFronzo RA; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):394-402. PubMed ID: 25633662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J
    Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
    Forst T; Uhlig-Laske B; Ring A; Graefe-Mody U; Friedrich C; Herbach K; Woerle HJ; Dugi KA
    Diabet Med; 2010 Dec; 27(12):1409-19. PubMed ID: 21059094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
    Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Diabetes Obes Metab; 2015 Feb; 17(2):136-44. PubMed ID: 25298165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR; Swallow R; Dugi KA; Woerle HJ
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
    Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ;
    Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R; Espadero RM; Jones R; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
    Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
    Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
    Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
    Schernthaner G; Barnett AH; Patel S; Hehnke U; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1078-86. PubMed ID: 24865132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Haak T; Meinicke T; Jones R; Weber S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Jun; 14(6):565-74. PubMed ID: 22356132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
    Woo V
    Int J Clin Pract; 2015 Dec; 69(12):1427-37. PubMed ID: 26303997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
    Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.